Target Price | $96.90 |
Price | $58.58 |
Potential |
65.41%
register free of charge
|
Number of Estimates | 30 |
30 Analysts have issued a price target Biomarin Pharmaceutical 2026 .
The average Biomarin Pharmaceutical target price is $96.90.
This is
65.41%
register free of charge
$128.10
118.68%
register free of charge
$65.65
12.07%
register free of charge
|
|
A rating was issued by 35 analysts: 28 Analysts recommend Biomarin Pharmaceutical to buy, 7 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Biomarin Pharmaceutical stock has an average upside potential 2026 of
65.41%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion $ | 2.85 | 3.21 |
17.97% | 12.34% | |
EBITDA Margin | 21.49% | 28.23% |
109.64% | 31.37% | |
Net Margin | 14.96% | 21.08% |
115.83% | 40.94% |
32 Analysts have issued a sales forecast Biomarin Pharmaceutical 2025 . The average Biomarin Pharmaceutical sales estimate is
This results in the following potential growth metrics:
12 Analysts have issued an Biomarin Pharmaceutical EBITDA forecast 2025. The average Biomarin Pharmaceutical EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
31 Biomarin Pharmaceutical Analysts have issued a net profit forecast 2025. The average Biomarin Pharmaceutical net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | 2.17 | 3.52 |
146.59% | 62.21% | |
P/E | 16.64 | |
EV/Sales | 3.25 |
31 Analysts have issued a Biomarin Pharmaceutical forecast for earnings per share. The average Biomarin Pharmaceutical EPS is
This results in the following potential growth metrics and future valuations:
Biomarin Pharmaceutical...
Analyst | Rating | Action | Date |
---|---|---|---|
Guggenheim |
Locked
➜
Locked
|
Locked | Aug 06 2025 |
UBS |
Locked
➜
Locked
|
Locked | Aug 05 2025 |
Morgan Stanley |
Locked
➜
Locked
|
Locked | Jul 22 2025 |
JP Morgan |
Locked
➜
Locked
|
Locked | Jul 14 2025 |
Goldman Sachs |
Locked
➜
Locked
|
Locked | May 05 2025 |
Citigroup |
Locked
➜
Locked
|
Locked | May 02 2025 |
Oppenheimer |
Locked
➜
Locked
|
Locked | Feb 24 2025 |
Analyst Rating | Date |
---|---|
Locked
Guggenheim:
Locked
➜
Locked
|
Aug 06 2025 |
Locked
UBS:
Locked
➜
Locked
|
Aug 05 2025 |
Locked
Morgan Stanley:
Locked
➜
Locked
|
Jul 22 2025 |
Locked
JP Morgan:
Locked
➜
Locked
|
Jul 14 2025 |
Locked
Goldman Sachs:
Locked
➜
Locked
|
May 05 2025 |
Locked
Citigroup:
Locked
➜
Locked
|
May 02 2025 |
Locked
Oppenheimer:
Locked
➜
Locked
|
Feb 24 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.